Latest Antiandrogens Stories
-- Findings Presented at American Society of Clinical Oncology 2009 Annual Meeting and Included in Best of ASCO(R) Educational Program -- SAN FRANCISCO, June 2 /PRNewswire-FirstCall/ -- Medivation, Inc.
Access to Late-Stage, First-in-Class Prostate Cancer Treatment Strengthens Presence in Oncology NEW BRUNSWICK, N.J., and LOS ANGELES, May 21 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ) and Cougar Biotechnology, Inc.
A new therapy for metastatic prostate cancer has shown considerable promise in early clinical trials involving patients whose disease has become resistant to current drugs.
- Seminal Research on Prostate Cancer Resistance Leads to Development of MDV3100, Novel Drug Candidate - SAN FRANCISCO, April 7 /PRNewswire-FirstCall/ -- Medivation, Inc.
Johns Hopkins scientists identify receptor type that makes cancer cells resistant to therapy, more aggressive
Hormone deprivation therapy that prostate cancer patients often take gives them only a temporary fix, but U.S. researchers suggest why.
Ariad Pharmaceuticals has reported encouraging preclinical data on the investigational mTOR inhibitor, deforolimus, alone or in combination with the anti-androgen agent, bicalutamide, in models of prostate cancer.
Cougar Biotechnology, Inc.
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today presented preclinical data on the investigational mTOR inhibitor, deforolimus, alone or in combination with the anti-androgen agent, bicalutamide, in models of prostate cancer.
Ariad Pharmaceuticals, a developer of medicines to treat cancer, has announced the initiation of a Phase II clinical trial by Merck & Co to evaluate the safety and efficacy of oral deforolimus, Ariad's investigational mTOR inhibitor, in patients with advanced prostate cancer.
- To befool; deceive; balk; jilt.
- An illusion; a trick; a cheat.